New eye injection shows promise for rare eye cancer
NCT ID NCT07402876
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an eye injection of ADX-2191 (a form of methotrexate) in 20 adults with primary vitreoretinal lymphoma, a rare eye cancer. The goal is to see if it safely clears cancer cells from the eye. Participants receive injections at different frequencies over 8 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VITREORETINAL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bascom Palmer Eye Institute
RECRUITINGMiami, Florida, 33101, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••